Clinical Study On Xuduanyin For Treatment Of Diabetic Nephropathy3～5Phase Of Blood Stasis And Water Diffusion Due To Kidney Deficiency

Objective: to observe clinical through Xuduanyin for treatment of diabeticnephropathy3~5phase of treatment blood stasis syndrome of water stop kidney emptyefficacy, safety, and to delay the progress of DN renal insufficiency provides new ideas.Methods: a randomized, open and positive drug parallel-group clinical researchmethod, observation DN3-5patients60cases, divided into the treatment group and controlgroup each30cases, two groups of all use diet control, symptomatic treatment and westernmedicine foundation treatment, the treatment group based on the break to drink to add andsubtract, water frying uniform, day one agent;8weeks of treatment. Results:(1) the kidneyfunction comparison: treatment after eight weeks, two groups of Scr are rising, Ccrdecreased, but before and after treatment group is no significant differences, P more than0.05; And the control group before and after treatment significant difference (P <0.05).Explain the treatment group in the stable kidney function better than control group.(2)sugar metabolism is: treatment group and control group are very significantly reduceglycated hemoglobin, fasting blood sugar and two hours after a meal blood sugar (P <0.01), the treatment group was significantly more reduce glycated hemoglobin, fastingblood sugar and two hours after a meal blood sugar (P <0.01). Explain the treatment groupsugar metabolism in improving better than control group.(3) syndromes curative effect is:after treatment, the two groups of patients8weeks of TCM syndrome total credit andbefore treatment are significant difference compared (P <0.05), and the treatment group ofTCM syndrome total score was significantly lower than the control group (P <0.05).(4)comprehensive curative effect is: in the treatment of8weeks, two groups of patients totalscore and treatment effect before all have significant difference compared (P <0.05), andthe treatment group of TCM syndrome total score was significantly lower than the controlgroup (P <0.05). Conclusion: Xuduanyin for DN treatment function can better improve the clinicalsymptoms and signs.